Efficacy and safety of fourth-generation CD19 CAR-T expressing IL7 and CCL19 along with PD-1 monoclonal antibody for relapsed or refractory large B-cell lymphoma

被引：0
|
作者：
俞腾
机构：
[1] Med Coll
[2] Zhejiang Univ
[3] Dept Hematol
[4] 2nd Affil Hosp
来源：
China Medical Abstracts (Internal Medicine) | 2024年 / 41卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R733.1 [网状内皮系统肿瘤];
学科分类号：
100214 ;
摘要：
Objective To explore the efficacy and safety of fourthgeneration chimeric antigen receptor T-cells (CAR-T),which express interleukin 7 (IL7) and chemokine C-C motif ligand 19 (CCL19) and target CD19,in relapsed or refractory large B-cell lymphoma.Methods Our center applied autologous 7×19 CAR-T combined with tirelizumab to treat 11 patients with relapsed or refractory large B-cell lymphoma.The efficacy and adverse effects were explored.
引用
收藏
页码：59 / 59
页数：1
相关论文
共 50 条
  • [1] Safety and Feasibility of Anti-CD19 CAR-T Expressing IL-7 and CCL19 in Patients with Relapsed or Refractory Large BCell Lymphoma
    Lei, Wen
    Ai, Zhao
    Liu, Hui
    Yang, Chunmei
    Wei, Cheng
    Guo, Shanshan
    Chen, Zhilu
    Guo, Qunyi
    Li, Linjie
    Zhao, Mingzhe
    Wu, Gongqiang
    Zhang, Jinyi
    Gao, Jimin
    Qian, Wenbin
    BLOOD, 2022, 140 : 12722 - 12722
  • [2] Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma
    Lei, Wen
    Zhao, Ai
    Liu, Hui
    Yang, Chunmei
    Wei, Cheng
    Guo, Shanshan
    Chen, Zhilu
    Guo, Qunyi
    Li, Linjie
    Zhao, Mingzhe
    Wu, Gongqiang
    Ouyang, Guifang
    Liu, Ming
    Zhang, Jinyi
    Gao, Jimin
    Qian, Wenbin
    CELL DISCOVERY, 2024, 10 (01)
  • [3] Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma
    Wen Lei
    Ai Zhao
    Hui Liu
    Chunmei Yang
    Cheng Wei
    Shanshan Guo
    Zhilu Chen
    Qunyi Guo
    Linjie Li
    Mingzhe Zhao
    Gongqiang Wu
    Guifang Ouyang
    Ming Liu
    Jinyi Zhang
    Jimin Gao
    Wenbin Qian
    Cell Discovery, 10
  • [4] Knockout IL4I1 affects macrophages to improve poor efficacy of CD19 CAR-T combined with PD-1 inhibitor in relapsed/refractory diffuse large B-cell lymphoma
    Rui Zhang
    Yi Zhang
    Hairong Xiao
    Qingxi Liu
    Mingfeng Zhao
    Journal of Translational Medicine, 23 (1)
  • [5] Safety and Efficacy of CD19 CAR-T Cells Co-Expressing IL-7 and CCL19 in Combination with Anti-PD-1 Antibody for Refractory/Relapsed DLBCL: Preliminary Data from the Phase.b Trial (NCT04381741)
    Qian, Wenbin
    Zhao, Aiqi
    Liu, Hui
    Lei, Wen
    Liang, Yun
    Yuan, Xianggui
    BLOOD, 2021, 138 : 3843 - +
  • [6] A phase I trial using CD19 CAR-T expressing PD-1/CD28 chimeric switch-receptor for refractory or relapsed B-cell lymphoma.
    Liu, Hui
    Lei, Wen
    Zhang, Chaoting
    Yang, Chunmei
    Wei, Juying
    Guo, Qunyi
    Guo, Xiaojun
    Chen, Zhilu
    Lu, Ying
    Lu, Zheming
    Qian, Wenbin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
    Roddie, Claire
    Lekakis, Lazaros J.
    Marzolini, Maria A. V.
    Ramakrishnan, Aravind
    Zhang, Yiyun
    Hu, Yanqing
    Peddareddigari, Vijay G. R.
    Khokhar, Nushmia
    Chen, Robert
    Basilico, Silvia
    Raymond, Meera
    Vargas, Frederick Arce
    Duffy, Kevin
    Brugger, Wolfram
    O'Reilly, Maeve A.
    Wood, Leigh
    Linch, David C.
    Peggs, Karl S.
    Bachier, Carlos
    Budde, Elizabeth Lihua
    Batlevi, Connie Lee
    Bartlett, Nancy
    Irvine, David
    Tholouli, Eleni
    Osborne, Wendy
    Ardeshna, Kirit M.
    Pule, Martin A.
    BLOOD, 2023, 141 (20) : 2470 - 2482
  • [8] The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma
    Duan, Deming
    Wang, Keke
    Wei, Cheng
    Feng, Dudu
    Liu, Yonghua
    He, Qingyan
    Xu, Xing
    Wang, Chunling
    Zhao, Shuping
    Lv, Leili
    Long, Jing
    Lin, Danni
    Zhao, Ai
    Fang, Bingmu
    Jiang, Jinhong
    Tang, Shixing
    Gao, Jimin
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [9] CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?
    Kinoshita, Hannah
    Bollard, Catherine M.
    Toner, Keri
    SEMINARS IN HEMATOLOGY, 2023, 60 (05) : 329 - 337
  • [10] Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
    Hirayama, Alexandre Vinaud
    Fiorenza, Salvatore
    Gauthier, Jordan
    Voutsinas, Jenna M.
    Wu, Qian Vicky
    Kimble, Erik L.
    Pender, Barbara S.
    Kirchmeier, Delaney R.
    Di, Henna A.
    Cassaday, Ryan D.
    Chapuis, Aude G.
    Green, Damian J.
    Kiem, Hans-Peter
    Milano, Filippo
    Shadman, Mazyar
    Till, Brian G.
    Riddell, Stanley R.
    Maloney, David G.
    Turtle, Cameron J.
    BLOOD, 2022, 140 : 7447 - 7449
12345